Wall Street View Pharmaceutical Executives’ 2013 © yright ibution p istr Co l D nload, rcia n dow Pipelinem Re eeprs caort m us use Co orised sonal or . Auth or per ale hibited copy f r S se pro ingle t fo ised u rint a s AlzhNeimoer’s Daiustehaosre: Movi nangd F porward Un y, view displa Drug Name Company Phase Launch Date Sales Potential Solanezumab III N/A N/A Gantenerumab II/III N/A N/A Hepatitis C: The More the Merrier Drug Name Company Phase Launch Date Sales Potential Sofosbuvir III 2014 Blockbuster Simeprevir/Daclatasvir III 2014/2015 Minibuster ABT-450 III 2015 Blockbuster Setrobuvir/Danoprevir/ II 2015 Minibuster Mericitabine Sovaprevir II N/A N/A Rheumatoid Arthritis: Return of the DMARDS Drug Name Company Phase Launch Date Sales Potential Tofacitinib Preregistration 2012/2013 Blockbuster Baricitinib II N/A N/A Fostamatinib III 2014 Minibuster GLPG 0634 II 2017 N/A Canadian Pharmaceutical Marketing l June/July 2013 7 Wall Street View Cancer: Improving on Innovation Drug Name Company Phase Launch Date Sales Potential GDC-0973 III N/A N/A Dabrafenib Preregistered 2013 Minibuster Trametinib Preregistered 2013 Minibuster Nivolumab II 2015 Blockbuster Trastuzumab Emtansine Preregistration 2013 Blockbuster 3 Radium-223 Chloride III N/A Blockbuster ARN 509 I/II N/A N/A Ponatinib Preregistration 2013 Minibuster Ibrutinib III 2014 Blockbuster Diabetes: Incremental Improvement Drug Name Company Phase Launch Date Sales Potential Tresiba Preregistered 2013 Blockbuster Ryzodeg Preregistered 2013 Blockbuster LY2605541 & LY2963016 III 2015 Blockbuster Canagliflozin Preregistration 2014 Blockbuster 8 Canadian Pharmaceutical Marketing l June/July 2013 Wall Street View Hyperlipidemia: CETP Inhibitors, PCSK9 Inhibitors, and More Drug Name Company Phase Launch Date Sales Potential Alirocumab III 2016 Blockbuster AMG 145 III 2016 Blockbuster Anacetrapib III 2016 Blockbuster Multiple Sclerosis: We’ve Got Your Number Drug Name Company Phase Launch Date Sales Potential Lemtrada Preregistered 2013 Minibuster Laquinimod III 2015 Minibuster Top Therapeutic Areas by Late-stage Products Therapeutic Category Estimated Global Sales 2018 ($US million) Oncology and Immunomodulators 16,668 Central Nervous System 13,891 Systemic Anti-infectives 13,600 Endocrine 7,627 Cardiovascular 5,794 Musculoskeletal 5,647 Respiratory 2,938 Blood 2,386 Late-stage includes Phase III and Filed Forecast data courtesy of EvaluatePharma * Source: Adapted from Pharmaceutical Executive “Pharm Exec’s 2013 Pipeline Report,” written by Ben Comer, Senior Editor, November 2012; Volume 32, Number 11. CPM Canadian Pharmaceutical Marketing l June/July 2013 9.